PRLD
HealthcarePrelude Therapeutics Incorporated
$2.44
$-0.29 (-10.62%)
Jan 5, 2026
Price History (1Y)
Analysis
Prelude Therapeutics Incorporated is a healthcare-focused biotechnology company with a market capitalization of $153.39 million and revenue of $10.50 million in the trailing twelve months. The company operates on a relatively small scale with 131 employees. The financial health of Prelude Therapeutics Incorporated is characterized by significant losses, as evidenced by a net income of -$111,772,000 and an EBITDA of -$119,267,000 over the same period. Despite this, the company has managed to maintain a gross margin of 100.0% and a current ratio of 3.21, indicating some liquidity. The balance sheet is somewhat leveraged, with a debt-to-equity ratio of 30.50. The valuation context for Prelude Therapeutics Incorporated is marked by negative earnings and an implied forward price-to-earnings ratio of -2.13. The company's revenue growth over the past year has been substantial, increasing by 116.7%. However, it does not pay dividends to shareholders, as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Visit website →Key Statistics
- Market Cap
- $153.39M
- P/E Ratio
- N/A
- 52-Week High
- $4.22
- 52-Week Low
- $0.61
- Avg Volume
- 1.47M
- Beta
- 0.89
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 131